Clinical trial REASSURE
REASSURE, Radium-223 alpha Emitter Agent in Safety Study in mCRPC popUlation for long-teRm Evaluation (Bayer 16913)
Cancers | |
---|---|
Organ | prostate |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Prospective observational study
|
Phase | Trial phase 4 |
Academic trial | Non |
Sponsor | Bayer |
BECT Identifier | B403201524066 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02141438 |
Inclusion criteria | - The treatment decision to Radium-223 needs to be made independent from andbefore patient enrollment in the study- Patients with histologically or cytologically confirmed castration resistantadenocarcinoma of the prostate with bone metastases |
Last update |